10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
| Revenue (TTM) | $618.58M |
| Gross Profit (TTM) | $445.15M |
| EBITDA | $-25.94M |
| Operating Margin | -10.70% |
| Return on Equity | -8.27% |
| Return on Assets | -3.89% |
| Revenue/Share (TTM) | $4.80 |
| Book Value | $6.41 |
| Price-to-Book | 9.16 |
| Price-to-Sales (TTM) | 12.49 |
| EV/Revenue | 11.5 |
| EV/EBITDA | 148.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.10% |
| Shares Outstanding | $120.21M |
| Float | $118.66M |
| % Insiders | 1.44% |
| % Institutions | 116.31% |
Volatility is currently expanding
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.
Powered by Anthropic's Claude, Sentira Single Cell enables researchers to analyze Chromium data using natural language, accelerating the path from scientific questions to experimental conclusions PLEASANTON, Calif., Nov. 2, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the commercial launch of Sentira Single Cell, a cloud-based agentic analysis application that puts sophisticated single cell insights at the fingertips of every researcher.
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
PLEASANTON, Calif., Oct. 27, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on Tuesday, November 17, at 4:30 p.m.
PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TXG and any ticker you trade — then tracks every position and per-strategy win rate.
